Drug Research
Nexelis acquires the GSK vaccines clinical bioanalytical laboratory located in Germany
Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to acquire its...
Drug Research
Lilly, Merus Ink Up-to-$1.6B Bispecific Antibody Partnership vs. Cancer
Eli Lilly’s oncology-focused Loxo Oncology at Lilly will partner with Merus to develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies, through a research collaboration and exclusive licensing agreement that could generate up to $1.6 billion for the...
News
CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021
The recently hosted CPhI & P-MEC China 2020 – organized by Informa Markets and CCCMHPIE and co-organized by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd. – attracted a remarkable 46,157 visits of professional pharma visitors, including 5,105 international...
Drug Research
ConserV Bioscience and Lawrence Livermore National Laboratory to Collaborate on Development of Broad-spectrum Coronavirus Vaccine
ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases and Lawrence Livermore National Laboratory (“LLNL”) have agreed to collaborate on the development of a broad-spectrum coronavirus vaccine.
This collaboration...
News
Aruvant Chooses Lonza to Manufacture ARU-1801, a Potentially Curative Treatment for Sickle Cell Disease, for Pivotal Trial
Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). Aruvant has chosen Lonza to help develop...
News
ViGeneron inks research pact with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
ViGeneron GmbH, a gene therapy company, announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited, for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent...
Drug Research
Novartis and GSK announce collaboration to support scientific research into genetic diversity in Africa
Novartis and GSK announced the launch of a collaboration to support high-quality scientific research investigating the link between genetic diversity across different regions in Africa and its potential impact on response to drug therapeutics.
The Project Africa Genomic Research Approach...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.















